Biomaterial Database

"DNCB reactivity in cancer patients and during follow-up period". 1982

U D Hardas, and S V Jalgaonkar

UI	MeSH Term	Description	Entries
D007111	Immunity, Cellular	Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.	Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D008297	Male		Males
D009369	Neoplasms	New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009578	Nitrobenzenes	BENZENE derivatives carrying nitro group substituents.
D001943	Breast Neoplasms	Tumors or cancer of the human BREAST.	Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004137	Dinitrochlorobenzene	A skin irritant that may cause dermatitis of both primary and allergic types. Contact sensitization with DNCB has been used as a measure of cellular immunity. DNCB is also used as a reagent for the detection and determination of pyridine compounds.	1-Chloro-2,4-Dinitrobenzene,2,4-Dinitrochlorobenzene,Benzene, 1-Chloro-2,4-Dinitro-,Chlorodinitrobenzene,DNCB,1 Chloro 2,4 Dinitrobenzene,2,4 Dinitrochlorobenzene
D005260	Female		Females
D005500	Follow-Up Studies	Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.	Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012882	Skin Tests	Epicutaneous or intradermal application of a sensitizer for demonstration of either delayed or immediate hypersensitivity. Used in diagnosis of hypersensitivity or as a test for cellular immunity.	Skin Test,Test, Skin,Tests, Skin

Related Publications

U D Hardas, and S V Jalgaonkar

DNCB reactivity in patients with skin carcinoma.

January 1974, Dermatologica,

U D Hardas, and S V Jalgaonkar

DNCB--reactivity in patients with leprosy in Kenya.

September 1976, Leprosy review,

U D Hardas, and S V Jalgaonkar

Self-Esteem and Coping Strategies in Adolescent Cancer Patients during the Period of Illness and Follow-Up.

April 2024, European journal of investigation in health, psychology and education,

U D Hardas, and S V Jalgaonkar

DNCB and PPD skin tests and prognosis in 152 patients with breast cancer. A prospective 2-year follow-up.

January 1985, Neoplasma,

U D Hardas, and S V Jalgaonkar

Decentralizing tuberculosis treatment: follow-up of patients during the transitional period.

July 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,

U D Hardas, and S V Jalgaonkar

DNCB--reactivity and skin irritation.

February 1973, The New England journal of medicine,

U D Hardas, and S V Jalgaonkar

DNCB reactivity and prognosis in 419 patients with malignant melanoma.

May 1981, Cancer,

U D Hardas, and S V Jalgaonkar

[Relapse and reinfection in gonorrhea during the follow-up period].

November 1977, Vestnik dermatologii i venerologii,

U D Hardas, and S V Jalgaonkar

Suicidal children grow up: psychiatric treatment during follow-up period.

July 1992, Journal of the American Academy of Child and Adolescent Psychiatry,